Bailard’s Allogene Therapeutics ALLO Stock Holding History

Bailard’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,600	Closed	-$125K	–	705
2022 Q3	$125K	Buy	+11,600	New	+$158K	0.01%	625
2021 Q4	–	Sell	-11,700	Closed	-$301K	–	719
2021 Q3	$301K	Buy	+11,700	New	+$278K	0.01%	532

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's ALLO Position: Q4 2022 in Review

Bailard sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 11,600 shares — an estimated $125K sold.

Bailard first reported a position in ALLO in Q3 2021 and held it in 2 quarters. The position peaked at $301K in Q3 2021. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

Bailard reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
Bailard sold 11,600 Allogene Therapeutics shares in Q4 2022, an estimated $125K.
Bailard first reported a position in Allogene Therapeutics in Q3 2021 and held it in 2 quarters.
Bailard's Allogene Therapeutics position peaked at $301K in Q3 2021.
168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.